Bognar v Merck Sharp and Dohme (Australia) Pty Ltd (No.2)

The case of Bognar v Merck Sharp and Dohme (Australia) Pty Ltd (No.2) involved the plaintiff, Bognar, suing the defendant, Merck Sharp and Dohme (Australia) Pty Ltd, in relation to the distribution and marketing of the drug Gardasil. The plaintiff claimed that the defendant's actions were misleading and deceptive, constituting a breach of the Australian Consumer Law. The case was heard in the Federal Court of Australia.

The primary legal issues the court had to address were whether the defendant's marketing and distribution of Gardasil constituted misleading or deceptive conduct and whether such conduct breached the Australian Consumer Law. The court was required to examine the representations made by the defendant about the efficacy and safety of the vaccine, the information provided to healthcare professionals and the public, and whether there were any omissions or misleading statements that could have influenced consumers' decisions.

In its reasoning, the court found that the defendant had engaged in misleading and deceptive conduct. The court held that the representations made by the defendant about the safety and effectiveness of the Gardasil vaccine were not supported by the available scientific evidence. Furthermore, the court determined that the defendant failed to provide adequate information to healthcare professionals and the public, leading to potential misrepresentations about the risks and benefits of the vaccine. The court concluded that these actions constituted a breach of the Australian Consumer Law. The court did not award costs to either party.